Zyndio 与 DEXASCAN 合作开发 From Scan to Plan，将 DEXA 体成分检测对接医生主导诊疗
Zyndio and DEXASCAN Announce Collaboration to Connect Body Composition Testing With Physician-Led Care
Zyndio 宣布与 DEXASCAN 合作开发 From Scan to Plan，拟将 DEXASCAN 超过 400 个检测网点与 Zyndio 远程医疗平台结合，把 DEXA 结果、实验室指标和生物标志物提交执业医师审阅。该模式拟用于 GLP-1 治疗患者的体成分监测，探索约 90、180 和 365 天的复查节点。公司称相关整合与诊疗路径尚未投入运营。
Proposed model links DEXA measurements, clinical evaluation and ongoing monitoring to inform preventive care.
, /PRNewswire/ -- Zyndio announced a collaboration with DEXASCAN to develop From Scan to Plan, connecting diagnostic measurements with clinical evaluation and follow-up care.
The proposed collaboration would combine DEXASCAN's network of more than 400 testing locations with Zyndio's telehealth platform, bringing DEXA findings, available laboratory results, biomarkers and supported health information to licensed medical providers for review.
Turning Measurements Into Clinical Context
DEXA assessments can measure body fat percentage, lean mass and regional body composition and, where available, estimate visceral fat. Follow-up measurements may help clinicians evaluate changes alongside clinical information.
"Healthcare has become excellent at generating data, but patients often struggle to understand what that information means and what to do next," said Brett Hudson, Founder and CEO of Zyndio. "Our vision is to connect measurement with meaningful clinical action. From Scan to Plan is about helping patients and their physicians turn disconnected health information into a more informed, continuous care experience."
"A DEXA scan gives people a clear picture of what their body is made of: fat, lean mass and bone. For years, the first question we've heard after a scan is, 'Now what?' This collaboration is designed to answer it," said Tony Orlando, Founder of DEXASCAN.COM. "The goal is that someone can establish their baseline at a location near them, have a licensed physician help turn those numbers into a plan, and then come back to measure whether it's working."
Potential Application in GLP-1 Care
An anticipated application is monitoring body composition in patients receiving GLP-1 treatment under medical supervision. DEXA measurements can distinguish changes in fat mass and lean mass. The proposed journey includes assessment, physician-led evaluation, monitoring and repeat scans at clinically appropriate intervals. Zyndio is exploring milestones of approximately 90, 180 and 365 days, subject to clinical needs and implementation planning.
Connecting Health Information
Zyndio is developing an ecosystem intended to connect diagnostic findings, laboratory biomarkers, supported wearable data and clinical care. "Healthcare doesn't have a shortage of data. It has a shortage of connections between the dots," said Matthew Trainer, Chief Technology Officer of Zyndio.
"A scan tells you where you are. Connecting those dots helps show where to go next. That's what we are building our AI-native platform to do."
The companies plan an implementation framework for patient engagement, information exchange and clinical coordination. Proposed integrations and care pathways are not operational.
About Zyndio
Zyndio connects eligible U.S. adults with licensed medical providers. Regulated treatments require clinical evaluation and provider approval. Prescriptions, when issued, are fulfilled through U.S.-licensed pharmacies. Zyndio is developing a preventive health ecosystem connecting clinical care with diagnostics, biomarkers and supported longitudinal health information. Zyndio.com
About DEXASCAN
DEXASCAN connects consumers with providers offering DEXA body composition testing through a nationwide network. Depending on location, services may include body composition DEXA, bone density testing, resting metabolic rate testing and VO2 max assessment. DEXASCAN.com
Media Contact
Brett Hudson | Founder and CEO | Zyndio, LLC
307-227-9322 | [email protected] | Zyndio.com
SOURCE Zyndio
来源：PR Newswire Health · prnewswire.com